Olema Pharmaceuticals, Inc. (OLMA)
NASDAQ: OLMA · Real-Time Price · USD
3.760
-0.350 (-8.52%)
At close: Mar 31, 2025, 4:00 PM
3.772
+0.012 (0.32%)
After-hours: Mar 31, 2025, 7:56 PM EDT

Company Description

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers.

The company’s lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors palbociclib and ribociclib, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, and with an mTOR inhibitor everolimus that is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer.

It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 for patients with ER+/HER2- metastatic breast cancer and other cancers which is in Phase 1 clinical trial.

The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009.

Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals logo
Country United States
Founded 2006
IPO Date Nov 19, 2020
Industry Biotechnology
Sector Healthcare
Employees 96
CEO Sean Bohen

Contact Details

Address:
780 Brannan Street
San Francisco, California 94103
United States
Phone 415 651 3316
Website olema.com

Stock Details

Ticker Symbol OLMA
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $19.00
CIK Code 0001750284
CUSIP Number 68062P106
ISIN Number US68062P1066
Employer ID 30-0409740
SIC Code 2834

Key Executives

Name Position
Dr. Sean P. Bohen M.D., Ph.D. President, Chief Executive Officer and Director
Shane William Charles Kovacs M.B.A. Chief Operating and Financial Officer
Dr. Naseem Zojwalla M.D. Chief Medical Officer
Shawnte M. Mitchell J.D. Chief Legal Officer and Corporate Secretary
Courtney O'Konek Vice President of Corporate Communications
Julie Dexter Senior Vice President and Head of People
Dr. David C. Myles Ph.D. Chief Discovery and Non-Clinical Development Officer
Sasha Austin CPA Vice President of Finance and Controller

Latest SEC Filings

Date Type Title
Mar 18, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 18, 2025 10-K Annual Report
Mar 18, 2025 8-K Current Report
Mar 5, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G/A Filing
Jan 15, 2025 EFFECT Notice of Effectiveness
Jan 15, 2025 EFFECT Notice of Effectiveness
Jan 15, 2025 424B5 Filing
Jan 15, 2025 424B3 Prospectus
Jan 13, 2025 SCHEDULE 13G/A Filing